Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant capecitabine versus observation after surgery for biliary tract cancer
2005-003318-13Phase 3Unknown
- Sponsor
- University of Southampton
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 2 more comparing Capecitabine adjuvant chemotherapy with Observation alone (2 arms). Primary endpoint: 2-year overall survival. Status: unknown.
02
Drugs
capecitabine
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)distal cholangiocarcinoma (dCCA)gallbladder cancer
Beyond the preview
Go deeper on 2005-003318-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003318-13.